Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Health Gets Australian Approval for Chemotoxicity Assay

NEW YORK — Yourgene Health said on Friday that it has received approval to sell its Elucigene DPYD chemotoxicity diagnostic assay in Australia.

The genotyping test, which was launched last year, is designed to identify cancer patients with dihydropyrimidine dehydrogenase deficiency, which can result in life-threatening side effects when the patients are treated with the chemotherapeutic agent 5-fluorouracil. 

According to Manchester, UK-based Yourgene, the test will be exclusively sold in Australia by its distribution partner, Southern Cross.

"We are extremely pleased to address another market with our first oncology test, which has already seen traction in the UK and Europe," Yourgene CEO Lyn Rees said in a statement.

Yourgene recently secured a contract for the Elucigene DPYD assay in the UK with a National Health Service trust.